Results 21 to 30 of about 6,343 (174)

Suppository treatment in ulcerative proctitis

European Journal of Inflammation, 2021
Ulcerative proctitis (UP) is a common form of ulcerative colitis (UC), the number of patients with UP is increasing. Suppository treatment containing mesalamine is usually the first-line choice for mild to moderate UP, here, we review the publications on
Yingjie Si, LanJun Shao, Shanqing Gao, Hongzhu Wen   +3 more
doaj   +1 more source

Successful management of HIV infection in a patient with ulcerative colitis; a case report [PDF]

Journal of Preventive Epidemiology, 2021
Human immunodeficiency virus (HIV) is an infectious disease that is rarely seen in ulcerative colitis patients. Both diseases commonly involve the colon.
Zain Majid, Shoaib Ahmed Khan, Hina Ismail, Nishat Akbar, Rajesh Mandhwani, Nasir Luck   +5 more
doaj   +1 more source

Myocarditis Secondary to Mesalamine-Induced Cardiotoxicity in a Patient with Ulcerative Colitis

Case Reports in Medicine, 2018
Development of cardiac manifestations in patients diagnosed with inflammatory bowel disease undergoing treatment with mesalamine is a rare. When this occurs, it can be difficult to tease out the primary etiology, as both IBD and mesalamine can cause ...
Kelechukwu U. Okoro, Matthew D. Roby, Adegbenga A. Bankole   +2 more
doaj   +1 more source

Anti-oxidant and anti-inflammatory potential of different polymer-based mesalamine delayed-release granules in TNBS-induced ulcerative colitis in wistar rats

Saudi Pharmaceutical Journal
Ulcerative colitis (UC) is an inflammatory condition of colon characterized by severe damage to the innermost colon tissues. A number of studies described the use of medication delivery systems based on natural polymers like polysaccharides for the ...
Imtiyaz Ahmed Najar, Archana Sharma, Abdulrahman Alshammari, Thamer H. Albekairi, Metab Alharbi, Taief Ahmad Dar, Zulfkar Latief Qadrie, Atul Kabra, A.M.J Newton, Manish Kumar   +9 more
doaj   +1 more source

Oral 5-Aminosalicylate, Mesalamine Suppository, and Mesalamine Enema as Initial Therapy for Ulcerative Proctitis in Clinical Practice with Quality of Care Implications

Canadian Journal of Gastroenterology and Hepatology, 2016
Background. Ulcerative proctitis (UP) is typically treated initially with oral 5-aminosalicylate (“5-ASA”), mesalamine suppository, or mesalamine enema (“UP Rx”). Little is known about their effectiveness in practice. Methods. Using a US health insurance
James M. Richter, Nabeela K. Arshi, Gerry Oster   +2 more
doaj   +1 more source

Design and Characterization of Mesalamine Loaded Nanoparticles for Controlled Delivery System [PDF]

Nanomedicine Research Journal, 2016
Objective(s): Nanoparticles (NPs) are known for their specific accumulation in the inflamed tissues of the colon and thus allow a selective delivery to the site of inflammation with minimum adverse effects.
Simin Seifirad, Hasan Karami, Shadab Shahsavari, Farzad Mirabasi, Farid Dorkoosh   +4 more
doaj   +1 more source

Bowel ultrasound scan in the management of pediatric moderate ulcerative colitis: The applicability of international bowel ultrasound segmental activity score

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives To evaluate bowel ultrasound (BUS) findings and the diagnostic and prognostic performance of international bowel ultrasound segmental activity score (IBUS‐SAS) in children with moderate ulcerative colitis (UC), including its accuracy for assessing endoscopic activity and predicting clinical remission and colectomy within 12 months ...
Martina Di Benedetto, Luca Scarallo, Camilla Pannacci, Sara Renzo, Monica Paci, Sara Naldini, Jacopo Barp, Laura Tasciotti, Paolo Lionetti   +8 more
wiley   +1 more source

Ocular facial myositis and sialadenitis presenting with new onset ulcerative colitis

JPGN Reports, EarlyView.
Abstract Extra‐intestinal manifestations of inflammatory bowel disease (IBD) can involve most organ systems, although the immunologic underpinnings are not well understood. Most patients who present with an extra‐intestinal manifestation have a single site of extra‐intestinal involvement; however, a small cohort presents with multiple different sites ...
Nicole Du, Nicole Mendez, Anil Darbari
wiley   +1 more source

The safe and effective use of tofacitinib and ustekinumab combination therapy in infantile onset inflammatory bowel disease

JPGN Reports, EarlyView.
Abstract Infantile‐onset inflammatory bowel disease (IOIBD) is a rare and severe subset of very‐early‐onset IBD, often associated with immune dysregulation and poor response to conventional therapies. Data regarding the use of Janus kinase inhibitors (JAKI) in this population is limited.
Smridhi Mahajan, Christian Wysocki, Bhaskar Gurram   +2 more
wiley   +1 more source

Review Article: The Impact of the Gut Microbiome on Ulcerative Colitis Pharmacotherapy

Alimentary Pharmacology &Therapeutics, EarlyView.
The gut microbiome modulates ulcerative colitis pharmacotherapy through microbial drug metabolism, immune regulation and altered drug bioavailability. Microbial composition influences response to aminosalicylates, corticosteroids, immunomodulators, biologics and small molecules, while microbiome‐targeted therapies show emerging promise.
Kate Collins, Srinivas Kamath, Rachel H. Davis, Samuel P. Costello, Robert V. Bryant, Alice S. Day, Paul Joyce   +6 more
wiley   +1 more source